The tentative contents is:

Demystifying Forecasting: Myths versus Reality; Performing a Strategic Value Assessments; What Is Forecast Value Added; Practical Applications and Methods in Forecasting; Tool Box Approach to Forecasting; Demand-Driven Consensus Forecasting; Performance Metrics; Cultural barriers in Forecasting.

Praise for Demand-Driven Forecasting

A Structured Approach to Forecasting

"There are authors of advanced forecasting books who take an academic approach to explaining forecast modeling that focuses on the construction of arcane algorithms and mathematical proof that are not very useful for forecasting practitioners. Then, there are other authors who take a general approach to explaining demand planning, but gloss over technical content required of modern forecasters. Neither of these approaches is well-suited for helping business forecasters critically identify the best demand data sources, effectively apply appropriate statistical forecasting methods, and properly design efficient demand planning processes. In Demand-Driven Forecasting, Chase fills this void in the literature and provides the reader with concise explanations for advanced statistical methods and credible business advice for improving ways to predict demand for products and services. Whether you are an experienced professional forecasting manager, or a novice forecast analyst, you will find this book a valuable resource for your professional development." --Daniel Kiely, Senior Manager, Epidemiology, Forecasting & Analytics, Celgene Corporation

"Charlie Chase has given forecasters a clear, responsible approach for ending the timeless tug of war between the need for 'forecast rigor' and the call for greater inclusion of 'client judgment.' By advancing the use of 'domain knowledge' and hypothesis testing to enrich base-case forecasts, he has empowered professional forecasters to step up and impact their companies' business results favorably and profoundly, all the while enhancing the organizational stature of forecasters broadly." --Bob Woodard, Vice President, Global Consumer and Customer Insights, Campbell Soup Company

Key Topics Covered:

Foreword. Preface. Acknowledgments. Chapter 1: Demystifying Forecasting: Myths versus Reality. Chapter 2: What Is Demand-Driven Forecasting? Chapter 3: Overview of Forecasting Methods. Chapter 4: Measuring Forecast Performance. Chapter 5: Quantitative Forecasting methods using time series data Chapter 6: Quantitative Forecasting Methods Using Causal Data. Chapter 7: Weighted Combined Forecasting Methods. Chapter 8: Sensing, Shaping, and Linking Demand to Supply: A Case Study Using MTCA. Chapter 9: Strategic Value Assessment: Assessing the Readiness of Your Demand Forecasting Process. Index.

For more information visit http://www.researchandmarkets.com/research/a97ba1/demanddriven_fore

SOURCE: Research and Markets

Research and Markets 
Laura Wood, Senior Manager, 
press@researchandmarkets.com 
U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716

In a press release out on October 30, Celgene Corporation to Present at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference

SUMMIT, N.J., Oct 30, 2009 -- Celgene Corporation (NASDAQ: CELG) today announced its presentation at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference on Wednesday, November 4, 2009 at 10:15 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company.

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) trading at $0.39 per share on trading volume of 95,321 shares.

In a press release out on October 30, Sunesis Completes Enrollment of Voreloxin REVEAL-1 Trial in Acute Myeloid Leukemia

SOUTH SAN FRANCISCO, Calif., Oct 30, 2009 -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported that it has completed enrollment in the REVEAL-1 (Response Evaluation of VorEloxin in AmL) trial, a Phase 2 dose regimen optimization trial of single agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML) patients who are unlikely to benefit from standard induction chemotherapy. A total of 113 patients were enrolled and dosed according to one of three dosing schedules.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis, please visit http://www.sunesis.com.

Gulfport Energy Corporation (Nasdaq:GPOR) trading at $7.57 on a volume of 103,596 shares

In a press release out on October 30, Gulfport Energy Corporation Schedules Third Quarter 2009 Financial and Operational Results Conference Call

OKLAHOMA CITY, Oct 30, 2009 -- Gulfport Energy Corporation (Nasdaq:GPOR) will hold a conference call on Thursday, November 5, 2009 at 1:00 p.m. CST to discuss its third quarter 2009 financial and operational results. The call will follow the release of Gulfport's third quarter 2009 earnings the morning of November 5, 2009.

About Gulfport

Gulfport Energy Corporation is an Oklahoma City-based independent oil and natural gas exploration and production company with its principal producing properties located along the Louisiana Gulf Coast and the Permian Basin in West Texas. Gulfport also holds a sizeable acreage position in the Alberta Oil Sands in Canada through its interest in Grizzly Oil Sands ULC.

ARYx Therapeutics, Inc. (NASDAQ:ARYX) trading at $2.29 on a volume of 22,306 shares

In a press release out on October 30, ARYx to Present at the Oppenheimer Annual Healthcare Conference

FREMONT, Calif., Oct 30, 2009 -- ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at the Oppenheimer 20th Annual Healthcare Conference in New York on November 4, 2009 at 10:15 am Eastern. A live Webcast of the presentation, together with the presentation slides, may be accessed at the ARYx Website http://www.aryx.com. The presentation will be archived for 30 days following the presentation.

About ARYx Therapeutics, Inc.

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered products designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has four products in clinical development: an oral anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone (ATI-2042); a prokinetic agent for the treatment of various gastrointestinal disorders, ATI-7505; an oral anticoagulant agent for patients at risk for the formation of dangerous blood clots, tecarfarin (ATI-5923); and, an agent for the treatment of schizophrenia and other psychiatric disorders, ATI-9242. Please visit the ARYx Website atwww.aryx.com for additional information.

Xtremepicks.com profiles early stage microcap and growth stocks that provide innovative products or services resulting in potentially "hyper-growth" opportunities. Often, these companies have yet to be recognized by Wall Street and the undiscovered nature of Xtremepicks.com's profile companies provide our members the opportunity to learn about these companies at their development stage, and more importantly before they possibly "turn the corner" and get exposed to a much larger investing audience.

Xtremepicks.com (www.Xtremepicks.com) has prepared all material herein based upon information believed to be reliable. The information contained herein is not guaranteed by Xtremepicks.com to be accurate, and should not be considered to be all-inclusive. Xtremepicks.com is a leading information resource for evaluating investment opportunities in small and microcap stocks. We focus on a limited number of companies in order to provide comprehensive coverage, including unique investment related features not available anywhere else on the Internet. To feature a company or to get more information, please visit us at www.Xtremepicks.com or email us at info@Xtremepicks.com Xtremepicks.coms affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value. Xtremepicks.com will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

To view full disclaimers, go to http://www.Xtremepicks.com/disclaimer.htm

CONTACT: Xtremepicks.com e-mail: Info@xtremepicks.com WWW: http://www.Xtremepicks.com

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

On 10/30/09, Celgene Corporation (NASDAQ:CELG) announced its presentation at the Oppenheimer & Co. Inc. 20th Annual Healthcare Conference on Wednesday, November 4, 2009 at 10:15 a.m. ET will be webcast live and will be available in the investor relations section of the company's Web site at www.celgene.com. Celgene management will provide an overview of the company.

On 10/30/09, ARYx Therapeutics, Inc. (NASDAQ:ARYX) announced it will present at the Oppenheimer 20th Annual Healthcare Conference in New York on November 4, 2009 at 10:15 am Eastern.

On 10/30/09, Javelin Pharmaceuticals, Inc. (NYSE:JAV), a leading developer and marketer of specialty pharmaceutical products for pain management, received commitments from a single institutional investor, to purchase up to 3,186,700 shares of its common stock for estimated gross proceeds of approximately $3.9 million.

Biotech investors interested in seeing more details about these stories and accessing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/fda-calendar/fda-calendar.html

Disclosure: No positions.

About BiomedReports.Com

BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content - including FDA and Clinical Trial Calendars plus a database that includes about 1,000 stocks and exchange-traded funds from the healthcare sector which are organized into various new healthcare stock indexes.

For more biomedical sector and investment news, go to www.BioMedReports.com

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects" "anticipates" "plans" "believes" "scheduled" "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BioMedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.

CONTACT: M. Davila, Editor, BioMedReports.Com e-mail: support@biomedreports.com Tel: +1 323 472 4480 Fax: +1 888 210 3556

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

--VIDAZA(R) Third Quarter Global Sales Increased 62% Y/Y and 12% Q/Q

--First Interim Analysis of MM-015 Phase III Study To Be Presented at American Society of Hematology Annual Meeting

Celgene Corporation (NASDAQ:CELG):

2009 Third Quarter Financial Results Year-Over-Year:

-- Non-GAAP Total Revenue Increased 18 Percent to $692 Million; GAAP Total Revenue $695 Million

-- REVLIMID Net Product Sales Increased 31 Percent to $450 Million

-- VIDAZA Net Product Sales Increased 62 Percent to $103 Million

-- THALOMID(R) Net Product Sales Totaled $110 Million

-- Non-GAAP Operating Income Increased 30 Percent to $292 Million; GAAP Operating Income $236 Million

-- Non-GAAP Net Income Increased 40 Percent to $260 Million; GAAP Net Income $217 Million

-- Non-GAAP Earnings Per Share Increased 40 Percent to $0.56 Per Diluted Share; GAAP Earnings $0.46 Per Diluted Share

Recent Developments And Highlights:

-- REVLIMID(R) Reimbursement Approvals In United Kingdom And Canada

-- Additional REVLIMID Regulatory Approvals in the Middle East and Latin America

-- Lancet Oncology Published Results From ECOG EA403 Phase III Trial, Demonstrating REVLIMID Plus Low-Dose Dexamethasone Is An Active Regimen For Patients With Newly Diagnosed Multiple Myeloma (MM)

-- NHL-001 Study Published In Journal Of Clinical Oncology Reported REVLIMID Demonstrated Single Agent Activity With Durable Responses In A Heavily Pretreated Patient Population

-- Advancing REVLIMID Solid Tumor Program In Prostate Cancer, Renal Cell Carcinoma, Pancreatic Cancer, and Colorectal Cancer

-- Journal Of Clinical Oncology Published Two Articles Highlighting Clinical Potential Of Pomalidomide As Treatment For MM and Myelofibrosis

-- VIDAZA(R) Upgraded By National Comprehensive Cancer Network (NCCN) To Preferred Therapy Based On Unprecedented Survival For Intermediate-2 And High-Risk Myelodysplastic Syndromes (MDS)

-- VIDAZA Now Listed By NCCN As Low Intensity Treatment Option For Patients With Acute Myeloid Leukemia

-- Initiated Phase II Trial Of ACE-011 For Treatment Of Chemotherapy Induced Anemia In Metastatic Breast Cancer

-- Completed Enrollment Of Phase I Proof-Of-Principle Study For Proprietary PDA-001 Placenta-Derived Stem Cells In Crohn's Disease

-- Celgene Cellular Therapeutics Patent Estate Highlighted In Nature Biotechnology

2009 Selected Corporate Objectives:

-- Maximize Global Clinical, Regulatory And Commercial Potential Of REVLIMID, VIDAZA, Pomalidomide, Apremilast, Amrubicin, ACE-011, PDA-001 And THALOMID(R)

-- Meet With EMEA, FDA and International Regulatory Agencies Regarding MM-015 Filing Strategy

-- Commercial Launch of REVLIMID In Australia

-- Gain Health Canada Regulatory Approval For VIDAZA In High-Risk MDS

-- Submit REVLIMID Regulatory Filing For Del 5q MDS In Japan

-- Advance REVLIMID Lymphoma Initiative Through More Than 60 Clinical Trials Worldwide, Including Novel Combinations In Multiple Patient Segments

-- Advance REVLIMID Chronic Lymphocytic Leukemia (CLL) Initiative Through More Than 40 Clinical Trials Worldwide

-- Complete Apremilast Phase II Study In Recalcitrant Psoriasis And Phase IIb Study In Moderate-To-Severe Psoriasis

-- Complete Enrollment of Amrubicin Phase III Trial In Patients With Small Cell Lung Cancer

Celgene Corporation (NASDAQ:CELG) announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40. Based on U.S. GAAP, Celgene reported net income of $216.8 million, or earnings per diluted share of $0.46 for the quarter ended September 30, 2009. GAAP net income for the third quarter of 2008 was $136.8 million, or earnings per diluted share of $0.29.

Celgene posted non-GAAP net income of $681.0 million or non-GAAP earnings per diluted share of $1.46 during the first nine months of 2009 as compared to non-GAAP net income of $517.9 million and non-GAAP earnings per diluted share of $1.13 in 2008. On a GAAP basis, Celgene reported net income of $522.5 million or earnings per diluted share of $1.12 for the first nine months of 2009, compared to GAAP net loss of $1.384 billion or a loss per diluted share of $3.17 in 2008, which was primarily due to an in-process research and development charge associated with the acquisition of Pharmion Corporation in March 2008.

"All key functional areas -- commercial, clinical, regulatory, and operations -- executed as planned globally and delivered an exceptional quarter," said Chairman and Chief Executive Officer Sol J. Barer, Ph.D. "We are looking forward to sharing significant clinical data with you across a broad range of Celgene compounds in the fourth quarter that will demonstrate the extraordinary global potential of our deep and diverse clinical pipeline."

Product Sales Performance

Non-GAAP total revenue was a record $692.2 million for the quarter ended September 30, 2009, an increase of 18 percent from 2008. GAAP total revenue was $695.1 million for the quarter ended September 30, 2009. The increase in total revenue was driven by global market share gains, reimbursement approvals, increased duration of therapy of REVLIMID(R) and the global growth of VIDAZA(R). REVLIMID net sales were $449.6 million, an increase of 31 percent over the same period in 2008. THALOMID(R) net sales (inclusive of Thalidomide Pharmion(TM) and Thalidomide Celgene(TM)) were $110.0 million. VIDAZA net sales were $103.1 million, an increase of 62 percent over sales in the third quarter of 2008. Revenue from Focalin(R) and the Ritalin(R) family of drugs totaled $25.8 million for the third quarter of 2009 compared to $23.8 million over the same period last year.

For the first nine months of 2009, non-GAAP total revenue was a record $1.919 billion, an increase of 19 percent year-over-year. GAAP total revenue was $1.929 billion for the nine months ended September 30, 2009. REVLIMID net sales for the first nine months of 2009 reached $1.209 billion, an increase of 27 percent over $955.2 million for the same period in 2008. THALOMID net sales for the first nine months of 2009 were $329.2 million. Vidaza net sales for the first nine months of 2009 reached $270.5 million, an increase of 97 percent over the same period in 2008, which excludes 2008 Vidaza sales prior to the March 7 acquisition of Pharmion.

Research and Development

To support clinical development and to advance global regulatory filings, the company increased R&D investments in multiple international clinical programs. For the third quarter of 2009, non-GAAP R&D expenses, which exclude share-based employee compensation expense, were $178.2 million compared to $149.9 million for the third quarter of 2008. These R&D expenditures continue to support ongoing clinical progress in multiple proprietary development programs for REVLIMID(R), pomalidomide and other IMiDs(R) compounds; VIDAZA(R); amrubicin, our lead compound for small cell lung cancer; apremilast and our other oral anti-inflammatory compounds; our kinase inhibitor programs; our Activin inhibitor program with ACE-011 and placenta-derived stem cell programs. On a GAAP basis, R&D expenses were $193.4 million for the third quarter of 2009 and $160.9 million for the same period in 2008.

Selling, General, and Administrative

Non-GAAP selling, general and administrative expenses, which exclude share-based employee compensation expense, were $172.3 million for the third quarter of 2009 compared to $152.0 million for the third quarter of 2008. The increase in expenses was due primarily to unrestricted donations to non-profit organizations for co-pay assistance. On a GAAP basis, selling, general and administrative expenses were $192.5 million for the third quarter of 2009 compared to $168.6 million for the third quarter of 2008.

Interest and Other Income, Net

For the quarter ended September 30, 2009, interest and other income, net, was $34.9 million compared to $21.6 million in the same period in 2008.

Cash, Cash Equivalents, and Marketable Securities

Celgene reported $2.764 billion in cash, cash equivalents, and marketable securities as of September 30, 2009.

Non-GAAP Financial Information

See the attached Reconciliation of GAAP to Non-GAAP Net Income (Loss) for an explanation of the amounts excluded and included to arrive at non-GAAP net income and non-GAAP earnings per share amounts for the three- and nine-month periods ended September 30, 2009 and 2008. Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis. Certain unusual or non-recurring items that management does not believe affect the company's basic operations do not meet the GAAP definition of unusual or non-recurring items. Non-GAAP net income and non-GAAP earnings per share are not, and should not be viewed as a substitute for similar GAAP items. We define non-GAAP diluted earnings per share amounts as non-GAAP net income divided by the weighted average number of diluted shares outstanding. Our definition of non-GAAP net income and non-GAAP diluted earnings per share may differ from similarly named measures used by others.

Conference Call and Webcast Information

Celgene will host a conference call to discuss the results and achievements of its third quarter 2009 and its operating and financial performance on October 22, 2009, at 9 a.m. EDT. The conference call will be available by webcast at www.celgene.com. An audio replay of the call will be available from noon October 22, 2009, until midnight EDT October 29, 2009. To access the replay, in the U.S. dial 888-203-1112; outside the U.S. dial 719-457-0820; and enter reservation number 9504107. The Company's fourth quarter 2009 financial and operational results will be reported on January 28, 2010.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the company's Web site at www.celgene.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as Form 10-K, 10-Q and 8-K reports.

Celgene Corporation and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except per share data)
                                                                                  Three Months Ended               Nine Months Ended
                                                                                  September 30,                    September 30,
                                                                                  2009             2008            2009           2008
Net product sales                                                                 $    667,967     $   567,017     $  1,842,353   $  1,541,556
Collaborative agreements and other revenue                                             2,381           2,402          6,979          9,960
Royalty revenue                                                                        24,789          23,046         79,524         75,011
                                 Total revenue                                         695,137         592,465        1,928,856      1,626,527
Cost of goods sold (excluding amortization of acquired intangible                      52,058          70,534         167,259        190,452
assets)
Research and development                                                               193,362         160,911        593,109        462,650
Selling, general and administrative                                                    192,512         168,607        542,264        485,345
Amortization of acquired intangible assets                                             21,111          32,833         67,403         77,842
Acquired in-process research and development                                           -               -              -              1,740,000
                                 Total costs and expenses                              459,043         432,885        1,370,035      2,956,289
Operating income (loss)                                                                236,094         159,580        558,821        (1,329,762 )
Equity in losses of affiliated companies                                               329             2,338          944            8,761
Interest and other income, net                                                         34,937          21,630         113,257        70,270
Income (loss) before income taxes                                                      270,702         178,872        671,134        (1,268,253 )
Income tax provision                                                                   53,887          42,058         148,602        116,138
Net income (loss)                                                                 $    216,815     $   136,814     $  522,532     $  (1,384,391 )
Per common share:
                                 Net income (loss) - basic                        $    0.47        $   0.30        $  1.14        $  (3.17      )
                                 Net income (loss) - diluted                      $    0.46        $   0.29        $  1.12        $  (3.17      )
Weighted average shares - basic                                                        458,834         456,509        459,332        437,206
Weighted average shares - diluted                                                      467,057         468,891        467,469        437,206
                                                                                  September30,     December31,
                                                                                  2009             2008
Balance sheet items:
                                 Cash, cash equivalents & marketable securities   $    2,764,448   $   2,222,091
                                 Total assets                                          5,082,286       4,445,270
                                 Stockholders' equity                                  4,109,099       3,491,328
Celgene Corporation and Subsidiaries
Reconciliation of GAAP to Non-GAAP Net Income (Loss)
(In thousands, except per share data)
                                                                                  Three Months Ended               Nine Months Ended
                                                                                  September30,                     September 30,
                                                                                  2009             2008            2009           2008
Net income (loss) - GAAP                                                          $    216,815     $   136,814     $  522,532     $  (1,384,391 )
              Before tax adjustments:
              Net product sales:
              Pharmion products to be divested                                  (1)       (2,902  )        (5,725  )        (9,367  )        (12,153   )
              Cost of goods sold (excluding amortization of acquired intangible
              assets):
              Share-based compensation expense                                  (2)       1,331            668              3,304            1,829
              Pharmion inventory step-up                                        (3)       -                7,545            354              18,668
              Pharmion products to be divested                                  (1)       1,127            2,450            5,395            5,014
              EntreMed intercompany royalty                                     (4)       (197    )        (398    )        (197    )        (398      )
              Research and development:
              Share-based compensation expense                                  (2)       15,178           10,964           44,841           32,264
              Upfront collaboration payments                                    (5)       -                -                34,500           45,000
              Selling, general and administrative:
              Share-based compensation expense                                  (2)       20,167           16,596           56,384           41,557
              Amortization of acquired intangible assets                        (6)       21,111           32,833           67,403           77,842
              Acquired in-process research and development                      (7)       -                -                -                1,740,000
              Equity in losses of affiliated companies:
              Equity in losses of EntreMed                                      (8)       321              763              980              2,821
              Net income tax adjustments                                        (9)       (13,115 )        (16,638 )        (45,119 )        (50,191   )
Net income - non-GAAP                                                                 $   259,836      $   185,872      $   681,010      $   517,862
Per common share -non-GAAP:
              Net income - basic                                                      $   0.57         $   0.41         $   1.48         $   1.18
              Net income - diluted                                              (10)  $   0.56         $   0.40         $   1.46         $   1.13
Explanation of adjustments:
(1)           Exclude sales and costs related to former non-core Pharmion Corp.
              products to be divested.
(2)           Exclude SFAS 123R share-based compensation expense for the third
              quarter totaling $36,676 in 2009 and $28,228 in 2008. The after
              tax net impact reduced GAAP net income for the third quarter by
              $28,585, or $0.06 per diluted share in 2009 and $22,253, or $0.05
              per diluted share in 2008. Exclude SFAS 123R share-based
              compensation expense for the nine-month periods totaling $104,529
              in 2009 and $75,650 in 2008. The after tax net impact reduced GAAP
              net income for the nine-month periods by $81,048, or $0.17 per
              diluted share in 2009 and $60,800, or $0.14 per diluted share in
              2008.
(3)           Exclude acquisition-related Pharmion Corp. inventory step-up
              adjustment to fair value expensed during the period.
(4)           Exclude the Company's share of THALOMID royalties payable to
              EntreMed, Inc.
(5)           Exclude upfront payments for research and development
              collaboration arrangements with GlobeImmune, Inc. and Array
              BioPharma Inc. of $30,000 and $4,500, respectively, for the
              nine-month period in 2009 and Acceleron Pharma, Inc. of $45,000
              for the nine-month period in 2008.
(6)           Exclude amortization of acquired intangible assets for the third
              quarter of 2009 and 2008 resulting from the acquisition of
              Pharmion Corp. of $21,111 and $32,833, respectively. Exclude
              amortization of acquired intangible assets for the nine-month
              periods from the acquisition of Pharmion Corp. of $67,403 in 2009
              and from the acquisitions of Pharmion Corp. and Penn T of $76,205
              and $1,637, respectively, in 2008.
(7)           Exclude the in-process research and development write-off related
              to the acquisition of Pharmion Corp. in the nine-month period in
              2008.
(8)           Exclude the Company's share of equity losses in EntreMed, Inc.
(9)           Net income tax adjustments reflects the tax effect of the above
              adjustments.
(10)          Diluted net income per share for the nine-month period of 2008 was
              determined using diluted weighted average shares of 459,304.

SOURCE: Celgene Corporation

Celgene Corporation 
David W. Gryska 
Sr. Vice President and Chief Financial Officer 
908-673-9059 
Brian P. Gill 
Vice President, Corporate Communications 
908-673-9530